Zhejiang Qixin Biotech

Zhejiang Qixin Biotech is a biopharmaceutical company based in Huzhou, China, specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary PROTAC (Proteolysis Targeting Chimera) platform to design small molecules that harness the body's natural protein disposal system to eliminate disease-causing proteins. Their primary focus is on addressing unmet medical needs in oncology, particularly hormone-driven cancers such as prostate and breast cancer. Qixin Biotech aims to overcome drug resistance associated with traditional inhibitors through its innovative degradation approach.